Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer

Схожие документы

• The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
  по: Tugnait, Meera, et al.
  Опубликовано: (2018)
• Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
  по: Tugnait, Meera, et al.
  Опубликовано: (2019)
• Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study
  по: Gupta, Neeraj, et al.
  Опубликовано: (2020)
• Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC
  по: Neeraj Gupta, et al.
  Опубликовано: (2022-05-01)
• Population pharmacokinetic analysis of axitinib in healthy volunteers
  по: Garrett, May, et al.
  Опубликовано: (2014)